The Wall Street Journal: Pfizer asks FDA to authorize its 3-dose COVID vaccine for children under 5


Pfizer Inc. and partner BioNTech SE asked U.S. health regulators to authorize three doses of their vaccine for children under 5 years.

The request Wednesday to the Food and Drug Administration comes after the companies said last month that three doses of the shot were 80% effective at preventing symptomatic COVID-19 and generated a robust immune response in children ages 6 months to 5 years old.

This article was originally published by Read the original article here.

Previous articleStocks lose ground Wednesday as Fed’s quantitative tightening looms
Next articleEnergy the lone sector rising, with ConocoPhillips stock at a record and Exxon Mobil at 8-year high


Please enter your comment!
Please enter your name here